Page 32 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $3.11
52wk Low $0.95 Immunic, Inc. IMUX $1.36
1200 Avenue of the Americas
New York, NY 10036

(USD - in millions) imux.com
Market Cap 129.5
Enterprise 84.2
Basic Shares Out. 89.93 COMPANY OVERVIEW
Float 49.38
Institutional Holdings 23.72% Detailed Analysis:Channelchek.com
Short Interest 3.03
Avg. 90-Day Volume 0.65 Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule therapies for
chronic inflammatory and autoimmune diseases. The company's lead
development program, vidofludimus calcium (IMU-838), is currently in
EPS Data phase 3 and phase 2 clinical trials for the treatment of relapsing and
progressive multiple sclerosis, respectively, and has shown therapeutic
2021 2022 2023 activity in phase 2 clinical trials in patients suffering from relapsing-
CQ1 (0.81) (0.74) (0.58) remitting multiple sclerosis, progressive multiple sclerosis and
CQ2 (0.82) (0.72) (0.54) moderate-to-severe ulcerative colitis.

CQ3 (0.76) (0.69) (0.51)
CQ4 (0.81) (0.59) (0.48)
CY (3.20) (2.75) (2.11) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.64
ROE (ttm) -131.28
Debt-to-Total Cap. (mrq) 4.41
Fiscal Year End 31-Dec
N
1200 Avenue o ew York NY 10036

Key Executives
CEO: Vitt, Daniel
CFO: Whaley, Glenn
COO: N/A
IR: Breu, Jessica
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures